Brokerages predict that Intrexon Corporation (NYSE:XON) will announce $55.94 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Intrexon Corporation’s earnings, with the lowest sales estimate coming in at $51.95 million and the highest estimate coming in at $62.06 million. Intrexon Corporation posted sales of $48.99 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 14.2%. The company is scheduled to report its next quarterly earnings results on Wednesday, November 8th.

On average, analysts expect that Intrexon Corporation will report full-year sales of $55.94 million for the current fiscal year, with estimates ranging from $214.80 million to $240.91 million. For the next financial year, analysts forecast that the company will post sales of $297.78 million per share, with estimates ranging from $255.84 million to $371.87 million. Zacks’ sales averages are a mean average based on a survey of analysts that cover Intrexon Corporation.

Intrexon Corporation (NYSE:XON) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.05. The firm had revenue of $54.40 million for the quarter, compared to analysts’ expectations of $57.17 million. Intrexon Corporation had a negative return on equity of 21.19% and a negative net margin of 76.32%. Intrexon Corporation’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.42) EPS.

Several equities analysts have weighed in on the stock. BidaskClub upgraded shares of Intrexon Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Northland Securities set a $30.00 price objective on shares of Intrexon Corporation and gave the stock a “buy” rating in a report on Monday. Finally, Zacks Investment Research upgraded shares of Intrexon Corporation from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a report on Tuesday, May 2nd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $40.50.

A number of large investors have recently bought and sold shares of XON. Federated Investors Inc. PA purchased a new stake in Intrexon Corporation during the second quarter worth approximately $172,000. Pacer Advisors Inc. raised its stake in Intrexon Corporation by 21.6% in the first quarter. Pacer Advisors Inc. now owns 7,352 shares of the biotechnology company’s stock worth $146,000 after buying an additional 1,305 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Intrexon Corporation during the first quarter worth approximately $164,000. Cullinan Associates Inc. bought a new position in Intrexon Corporation during the second quarter worth about $201,000. Finally, Biondo Investment Advisors LLC bought a new position in Intrexon Corporation during the first quarter worth about $214,000. 84.38% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Intrexon Corporation (NYSE XON) opened at 18.66 on Friday. The firm’s market cap is $2.23 billion. The firm’s 50-day moving average price is $23.08 and its 200-day moving average price is $21.96. Intrexon Corporation has a one year low of $17.74 and a one year high of $32.90.

COPYRIGHT VIOLATION WARNING: “$55.94 Million in Sales Expected for Intrexon Corporation (NYSE:XON) This Quarter” was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at

Intrexon Corporation Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Get a free copy of the Zacks research report on Intrexon Corporation (XON)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.